Did you mean leaf iodide?
Displaying drugs 576 - 600 of 703 in total
Alferminogene tadenovec
Alferminogene tadenovec, Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease. Alferminogene tadenovec represents a new therapeutic class of biologics designed to promote angiogenesis and thereby improve blood flow following a one-time intracoronary administration...
Investigational
Matched Description: … Alferminogene tadenovec, Cardium’s lead product candidate, is being developed for the potential treatment …
Odronextamab
Odronextamab is a hinge-stabilized, fully human immunoglobulin G4 (IgG4)-based CD20×CD3 bispecific antibody currently evaluated for the treatment of relapsed/refractory (R/R) B-Cell non-Hodgkin lymphoma (NHL).[A254187,A254197] Preliminary studies have shown that in patients with R/R NHL, the use of odronextamab does not lead to the development of neurologic toxicity; however, it can...
Investigational
Matched Description: … to the development of neurologic toxicity; however, it can lead to the development of cytokine release ... A254197] Preliminary studies have shown that in patients with R/R NHL, the use of odronextamab does not lead …
123I-iodometomidate
123I-iodometomidate is under investigation in clinical trial NCT00454103 (Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy).
Investigational
Diodone
Experimental
SB-559448
SB-559448 is a small-molecule drug that mimics the activity of thrombopoietin (TPO), a protein factor that promotes growth and production of blood platelets. This drug is developed by GlaxoSmithKline and used to treat Thrombocytopenia.Thrombocytopenia (decreased platelet count) is a common side effect of many chemotherapies and can lead to uncontrolled...
Investigational
Matched Description: … Thrombocytopenia.Thrombocytopenia (decreased platelet count) is a common side effect of many chemotherapies and can lead …
5-Iodo-2'-Deoxyuridine-5'-Monophosphate
Experimental
Iodo-Willardiine
Experimental
Zelavespib
Zelavespib (PU-H71) has been used in trials studying the treatment of LYMPHOMA, Solid Tumors, Metastatic Solid Tumor, and Myeloproliferative Neoplasms (MPN).
Investigational
Tetraiodothyroacetic acid
Experimental
Ropidoxuridine
Ropidoxuridine is a novel, orally available, thymidine analogue and prodrug for IUdR, which demonstrated a survival advantage in Phase II studies in anaplastic astrocytoma, a type of brain tumor.
Investigational
9-(3-IODOBENZYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE
Experimental
OSI-461
OSI-461 is a second-generation molecule belonging to a new class of drugs termed selective apoptotic anti-neoplastic drugs (SAANDs).
Investigational
N-(2-Aminoethyl)-1-aziridineethanamine
First described in the literature in 2004, N-(2-Aminoethyl)-1-aziridineethanamine is an experimental angiotensin converting enzyme 2 inhibitor investigated for its use in treating cardiovascular disease and its activity against Severe Acute Respiratory Syndrome (SARS).
Experimental
Fiacitabine
Fiacitabine has been used in trials studying the treatment of HIV Infections and Cytomegalovirus Infections.
Investigational
GI-5005
GI-5005 is GlobeImmune's lead infectious disease product from its proprietary Tarmogen active immunotherapy platform for the treatment of chronic hepatitis C infection. GI-5005 is whole, heat-killed recombinant yeast genetically modified to express HCV-specific protein targets. Tarmogens are believed to activate both an innate immune response via Toll-like receptors (TLRs), as...
Investigational
Matched Description: … GI-5005 is GlobeImmune's lead infectious disease product from its proprietary Tarmogen active immunotherapy …
Para-Iodo-D-Phenylalanine Hydroxamic Acid
Experimental
3-Methylthiofentanyl
3-Methyl-thiofentanyl is a fentanyl analog and an opioid analgesic that works by inducing central nervous system (CNS) depression.
Experimental
Illicit
MIP-1095 I-123
123 I Mip 1095 is under investigation in clinical trial NCT00712829 (Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents).
Investigational
Posizolid
Posizolid (AZD2563) is an oxazolidinone antibiotic. In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial results (though no results were reported).
Investigational
Tallimustine
Tallimustine, a benzoyl mustard derivative of distamycin A, is an alkylating agent that binds to the minor groove of DNA.[A182036,A182039] It's association with severe myelotoxicity lead to the end of its development in favour of α-halogenoacrylamide derivatives such as brostallicin, which have a favourable cytotoxicity/myelotoxicity ratio.[A182039,A182045] Newer generations of DNA...
Experimental
Matched Description: … [A182036,A182039] It's association with severe myelotoxicity lead to the end of its development in favour …
Displaying drugs 576 - 600 of 703 in total